Hyperhaemolysis in a pregnant woman with a homozygous β^0^-thalassemia mutation and two genetic modifiers

Lou Jiwu | Sun Manna | Meixiang Lai | Zhao Ying | Liu Yanhui

1Prenatal Diagnostic Center, Dongguan Maternal & Children Health Hospital, Dongguan, China
2Department of Obstetrics & Gynecology, Dongguan Maternal and Children Hospital, Dongguan, China
3Department of Obstetrics & Gynecology, Dongguan Gaobu Hospital, Dongguan, China

Correspondence
Liu Yanhui, Department of Prenatal Diagnosis Center, Dongguan Maternal and Child Health Hospital, Dongguan 523112, Guangdong, China.
Email: liuliang71215@163.com

Funding information
Medical Scientific Research Foundation of Guangdong Province, Grant/Award Number: A2019076

Abstract
Introduction: Patients with a homozygous β^0^-thalassemia mutation usually have a transfusion-dependent β-thalassemia major phenotype. However, some β-thalassemia patients present with a relatively mild and even normal phenotype and always have a high level of Hb F induced by genetic modifiers.

Methods: In this study, we identified a homozygous β^0^-thalassemia mutation (HBB: c.126_129delCTTT) in a 36-year-old pregnant woman. She had not presented any clinical symptoms of β-thalassemia since birth. To investigate her unexpected mild phenotype, known genetic modifiers that ameliorate the severity of β-thalassemia were analysed. Besides, we described the haematological changes during pregnancy.

Results: Two genetic modifiers (a heterozygous KLF1: c.519_525dup mutation; and two homozygous HBS1L-MYB locus SNP variants: rs7776054 and rs9399137) were identified. However, she showed a gradually decreased level of Hb during pregnancy, and serious transfusion complication of hyperhaemolysis was induced and complicated the pregnancy.

Conclusion: This report is in accordance with previous findings that genetic modifiers can ameliorate the clinical severity of β-thalassemia, even without obvious clinical symptoms in a prolonged steady state. However, the steady state can be disrupted during pregnancy. In addition, raising awareness of hyperhaemolysis among clinicians treating patients with thalassemia is necessary.

KEYWORDS
foetal haemoglobin, HBS1L-MYB, hyperhaemolysis, KLF1, β-thalassemia

INTRODUCTION

In southern China, there is a high prevalence of β-thalassemia (β-tha; Xiong et al., 2010; Xu et al., 2004; Yin et al., 2014). Homozygotes and compound heterozygotes for β-tha usually have a severe transfusion-dependent phenotype. However, some conditions that decrease the production of α-globin (α-thalassemia) or increase the production of γ-globin can improve the clinical severity (Galanello et al., 2009).

Several genetic modifiers that upregulate the expression of γ-globin have been identified (Chen et al., 2017; Razak et al., 2018). Deletions involving the β-globin locus (e.g. δβ^+^-thalassemia) usually have higher levels of γ-globin; two single-nucleotide polymorphisms (SNPs), rs7482144 (Xmn1
polymorphism) in HBG2 (OMIM: 142250) and rs368698783 in HBG1 (OMIM: 142200), have also been shown to increase γ-globin production. In addition to these SNPs in the β-globin locus, some modifiers involved genes or polymorphisms that were located on other chromosomes, including SNPs in the HBS1L-MYB intergenic region on chromosome 6q23 and the BCL11A gene (OMIM:606557) on chromosome 2p16, and mutations in the KLF1 gene (OMIM:600599) on chromosome 19p13.

However, the application of these modifiers in clinical practice, especially in prenatal diagnosis and genetic counselling of thalassemia, requires a more complete observation of phenotypic alterations in specific cases. Here, we provide a detailed description of clinical and molecular characteristics in a pregnant Chinese woman with a homozygous β-thal mutation, which could provide a straightforward example to determine the effect of genetic modifiers on the clinical severity of β-thal. In addition, the diagnosis and treatment of hyperhaemolysis in this patient indicated that raising awareness of such serious blood transfusion complications among clinicians treating patients with thalassemia is necessary.

2 | CLINICAL PRESENTATION

The proband was a 36-year-old, gravida 4, para 3, woman from Beiliu City, Guangxi Province in Southern China. She was born normally and had an unremarkable childhood and adolescence similar to her peers, without any noticeable development delay, jaundice, paleness, fatigue, dark-coloured urine and splenomegaly or hepatomegaly. During childhood and adolescence, she had never visited a doctor for anaemia.

Her first pregnancy was normal, and her second pregnancy was terminated early for social reasons. However, during her third pregnancy, she had a haemoglobin (Hb) level of 6.8 g/dl after postpartum blood loss of 490 ml; she did not receive prenatal thalassemia examination because her husband had a negative result. However, new-born thalassemia screening at a local hospital suggested that the first and third pregnancies, a daughter and a son currently 9 and 5 years old, respectively, were carriers for β-thal.

At 18 +1 weeks of gestation of the current (fourth) pregnancy, routine haematological evaluation revealed an Hb level of 10.1 g/dl, a mean cell volume (MCV) of 69 fl, a mean cell Hb (MCH) of 22.7 pg, an Hb A2 level of 2.0% and an Hb F level of 98%. At 22 +1 weeks of gestation, she was referred to us for amniocentesis due to a high risk for trisomy 21 and identified an expected heterozygous HBB: c.126_129delCTTT mutation in the foetus. The pregnancy continued. At 28 +1 weeks of gestation, she was admitted to a local hospital for vaginal bleeding induced by central placenta previa. Examination on admission showed an Hb level of 8.1 g/dl, a TBIL level of 21.9 µmol/L and a DBIL level of 7.8 µmol/L. She was treated with general measures. At 31 +3 weeks of gestation, she had an Hb level of 7.2 g/dl and received a transfusion of 2 units of leukocyte filtration erythrocytes, which was her first transfusion since birth. The transfusion process was normal.

At 34 +1 weeks of gestation, she was referred for termination of pregnancy. Examination on admission showed an Hb level of 9.9 g/dl, a TBIL level of 26.9 µmol/L and a lactate dehydrogenase level of 341 U/L (LDH, normal range 120–250). Urine was negative for Hb and erythrocytes. In view of her condition and the need for a caesarean section at any time, a second transfusion of 1.5 units of leukocyte filtration erythrocytes was administered to keep Hb >10.0 g/dl. However, posttransfusion Hb on the second day was 9.4 g/dl with TBIL 33.9 µmol/L. A third transfusion of 1.5 units of leukocyte filtration erythrocytes was administered, and similar lower posttransfusion Hb and higher bilirubin levels were observed. In addition, she presented dark brown urine and increased levels of urobilinogen (UBG, 140 µmol/L, normal range 3–16). Serologic analysis showed a positive antiglobulin test with anticomplement (C3d). Hyperhaemolysis was considered.

Five days later, her Hb level was 7.4 g/dl. In view of the falling Hb level and completion of urgent foetal lung maturation with dexamethasone, caesarean section was performed to terminate pregnancy. Intraoperative blood loss was approximately 500 ml, and the fourth transfusion with 3 units of leukocyte filtration erythrocytes was administered. Posttransfusion Hb was 7.8 g/dl. She was then admitted to the intensive care unit, and methylprednisolone was started.

Unfortunately, her Hb further dropped to 4.0 g/dl on day 3. A fifth transfusion of 4 units of leukocyte filtration erythrocytes was given. Similar to previous transfusion, her Hb gradually decreased with persistently elevated levels of bilirubin and LDH. Three days later, Hb dropped to 4.7 g/dl, with TBIL 20.3 µmol/L, DBIL 9.2 µmol/L and LDH 1456 U/L. In
addition, IgM anti-P1 and IgG anti-Jka<sup>+</sup> antibodies were identified after the last transfusion. In view of her condition, she was transferred to a superior hospital for further assessment and treatment (IV immunoglobulins were given). A month later, by telephone follow-up, she said she had recovered after 2 weeks of hospitalization. Haematological and clinical chemical indexes are summarized in Table 1.

The ethics committee of Dongguan Maternal and Children Hospital approved the study. Informed consent was obtained from participants (husband and wife).

3 | DISCUSSION

HBB: c.126_129delCTTT is a common β<sup>0</sup>-thalassemia mutation in Chinese individuals (Xu et al., 2004), for which most homozygous patients have a classic transfusion-dependent β-thalassemia major phenotype, with an average onset age of younger than 2 years old. However, the patient in our study had led a normal life since birth, without developmental delay, jaundice, paleness, fatigue, dark-coloured urine and splenomegaly or hepatomegaly.
The identification of homozygous mutations was made incidentally on routine haematological examination during pregnancy.

The mild phenotype was due to the high level of Hb F, which compensated for the loss of Hb A and ameliorated anaemia and disease severity. The KLF1 mutation is one of the genetic modifiers that upregulates the expression of the γ-globin gene. In 2014, Liu et al. found that the presence of KLF1 mutations in β-thalassemia patients could lead to a dramatic improvement in clinical severity, resulting in a thalassemia intermedia phenotype, with reduced transfusion requirements and Hb levels in the range 6.5–9.2 g/dl (Liu et al., 2014).

The patient in our study had a KLF1:c.519_525dup mutation, similar to most patients in the study by Liu et al. However, our patient was older and had a milder phenotype with transfusion independence. Given a usually relatively decreased Hb level during pregnancy, the nonpregnancy Hb level in our patient should not be lower than that of 10.1 g/dl at 17 weeks of gestation of the fourth pregnancy. The milder phenotype in our patient was due to homozygous HBS1L-MYB variants beyond the KLF1 mutation. The linked rs7776054 and rs9399137 SNPs have been shown to be associated with Hb F levels in Chinese β-thalassemia patients (Farrell et al., 2011; Lai et al., 2016). Our patient was similar to two Cypriot patients reported recently by Fanis et al. (2019). The Cypriot patients were homozygous for the β-thalassemia major HBB: c.93–21G>A mutation and heterozygous for the KLF1: c.968C>T mutation. They were phenotypically healthy, with

### Table 1: Changes of haematological and clinical chemical indexes during pregnancy and after transfusion

| Gestation/postpartum day | Day after transfusion | WBC (g/L) | RBC (T/L) | Hb (g/dl) | HCT (%) | MCV (fL) | MCH (pg) | PLT (g/L) | TBIL (umol/L) | DBIL (umol/L) | LDH (U/L) |
|-------------------------|---------------------|-----------|-----------|-----------|---------|---------|---------|----------|--------------|--------------|----------|
| Normal range 5–15       |                      | 3.5–5.5   | 11–15     | 31–34     | 80–100 | 27–34   | 100–300 | 0–21     | 0–5          | 120–250      |          |
| 18±1                    |                     | 13.61     | 4.45      | 10.1      | 30.7   | 69.0    | 22.7    | 234      |              |              |          |
| 22±1                    |                     | 12.66     | 3.92      | 9.0       | 26.8   | 68.4    | 23.0    | 187      |              |              |          |
| 24±3                    |                     | 12.07     | 3.81      | 8.6       | 26.8   | 70.3    | 22.6    | 169      | 23           | 7.9          |          |
| 28±3                    |                     | 11.81     | 3.49      | 8.1       | 25.4   | 72.8    | 23.2    | 186      | 21.9         | 7.8          |          |
| 31±3                    |                     | 11.51     | 3.1       | 7.2       | 22.4   | 72.0    | 23.0    | 176      |              |              |          |
| Transfusion (2 units)    |                     |           |           |           |        |         |         |          |              |              |          |
| 32±6                    | 10                  | 12.58     | 3.82      | 9.0       | 28.5   | 74.6    | 24.0    | 178      |              |              |          |
| 34±1                    |                     | 14.03     | 3.92      | 9.9       | 27.8   | 70.9    | 25.3    | 189      | 26.9         | 8.7          | 341      |
| Transfusion (1.5 units)  |                     |           |           |           |        |         |         |          |              |              |          |
| 34±2                    | 1                   | 13.08     | 4         | 9.7       | 29.1   | 72.8    | 24.3    | 154      |              |              |          |
| 34±3                    | 2                   | 13.05     | 3.81      | 9.4       | 28.3   | 74.3    | 24.7    | 148      | 33.9         | 11.2         |          |
| Transfusion (1.5 units)  |                     |           |           |           |        |         |         |          |              |              |          |
| 34±3                    | 1                   | 13.52     | 3.94      | 9.9       | 28.4   | 72.1    | 25.1    | 148      |              |              |          |
| 34±4                    | 2                   | 10.56     | 3.44      | 8.7       | 24.9   | 72.4    | 25.3    | 150      | 39.2         | 15.5         |          |
| 34±6                    | 4                   | 10.84     | 3.37      | 8.2       | 23.9   | 70.9    | 24.3    | 153      | 40.4         | 17.8         | 770      |
| 34±1                    | 5                   | 10.61     | 3.26      | 7.9       | 22.9   | 70.2    | 24.2    | 125      | 36.9         | 18           | 865      |
| 35±2                    | 6                   | 11.71     | 3.1       | 7.4       | 21.9   | 70.6    | 23.9    | 173      | 33.3         | 15.2         | 807      |
| Transfusion (3 units)    |                     |           |           |           |        |         |         |          |              |              |          |
| 0                       | 1                   | 16.14     | 3.08      | 7.8       | 22.5   | 73.1    | 25.3    | 164      | 66.1         | 31           | 929      |
| 1                       | 2                   | 13.38     | 2.38      | 5.8       | 17.2   | 72.3    | 24.4    | 148      | 39.6         | 24.7         | 951      |
| 2                       | 3                   | 8.7       | 1.71      | 4.0       | 12.3   | 71.9    | 23.4    | 149      | 27.1         | 14.9         | 764      |
| Transfusion (4 units)    |                     |           |           |           |        |         |         |          |              |              |          |
| 2                       | 1                   | 12.74     | 2.86      | 7.4       | 21.6   | 75.5    | 25.9    | 161      | 70.9         | 28.7         |          |
| 3                       | 2                   | 11.25     | 2.5       | 6.3       | 18.8   | 75.2    | 25.2    | 153      | 49           | 23           | 1188     |
| 4                       | 3                   | 6.95      | 2.01      | 4.9       | 14.7   | 73.1    | 24.4    | 140      | 39           | 19.2         |          |
| 5                       | 4                   | 8.78      | 2.04      | 4.7       | 15.1   | 74      | 23      | 151      | 20.3         | 9.2          | 1456     |

Abbreviations: DBIL, direct bilirubin level; Hb, haemoglobin; HCT, Haematocrit; LDH, lactate dehydrogenase; MCH, mean corpuscular haemoglobin; MCV, mean corpuscular volume; PLT, Platelet; RBC, red blood cell; TBIL, total bilirubin level; WBC, white blood cell.

Caesarean section was performed to terminate pregnancy; transfusion was given during operation.
near-normal levels of total haemoglobin (12.7–13.5 g/dl) and extremely high Hb F levels (63%–66.2%). However, the milder phenotype in Cypriot patients may be due to allelic heterogeneity: the KLF1 missense mutation (c.968C>T) in Cypriot patients probably upregulates the expression of the γ-globin gene by way different from the loss-of-function allele (KLF1: c.519_525dup). Of course, the possibility of other unknown modifiers ameliorating severity cannot be ruled out in Cypriot patients.

However, the steady state can be disturbed under certain conditions, as indicated by our patient. The low level of postpartum Hb at 6.8 g/dl after blood loss of 490 ml indicated that haemolysis should have been aggravated during the third pregnancy. During the fourth pregnancy, the Hb level obviously gradually decreased from 10.1 g/dl at 17 weeks of gestation to 7.2 g/dl at 31 weeks of gestation. Ultimately, blood transfusion was necessary for her condition. Unfortunately, a serious transfusion complication of hyperhaemolysis was induced.

Hyperhaemolysis is characterized by the destruction of both host and donor red blood cells via an unknown mechanism, which was diagnosed mainly based on (1) a posttransfusion Hb level that was lower than the pretransfusion Hb level, (2) the development of an elevated LDH or TBIL above the patient’s pretransfusion level and/or acute-onset haemoglobinuria and (3) the onset of symptoms between 2 and 21 days following RBC transfusion (Merrill et al., 2019). According to these criteria, hyperhaemolysis in our patient should have been triggered by the second transfusion. However, the diagnosis of hyperhaemolysis was made after the third transfusion because hyperhaemolysis has been mostly described in sickle cell disease, and we first attributed the lower Hb level after the second transfusion to suspicious bleeding induced by central placenta previa. Treatment of hyperhaemolysis is challenging. It is important to avoid further transfusion as much as possible and start immunosuppressive treatment (Danée et al., 2015). Further transfusion probably worsens haemolysis, causing more serious anaemia, which was seen in our patient. However, further transfusions are necessary for clinical reasons. In our patient, immunosuppressive treatment with methylprednisolone was unsuccessful, and she was transferred to a superior hospital for further assessment and treatment due to our unfamiliarity with hyperhaemolysis treatment.

The pathophysiology of hyperhaemolysis is unknown. Although the KLF1:c.519_525dup variant has been reported to cause an apparent dominantly inherited Lu(a-b-–) phenotype and anti-Lu(a) or anti-Lu(b) could cause delayed haemolytic transfusion reactions (Fraser et al., 2019; Thornton & Grimsley, 2019), it was impossible that the hyperhaemolysis in the pregnant woman was due to transfusion of mismatched Lutheran-typed red cells. Unlike the true Lu null phenotype, the Lu-(a-b-) phenotype caused by KLF1 mutations is due to a great reduction, but not loss, in Lu antigens. So the pregnant woman should not be at risk of development of anti-Lu in presence of weaken Lu antigens. However, serologic analysis showed presence of complement C3 after the third transfusion and IgM anti-P1 and IgG anti-Jka after the last transfusion. Similar conditions were noted to coincide with hyperhaemolysis in some previous descriptive reports Merrill et al. (2019). It may be that complement and alloimmunization played a role in initiation and development of the hyperhaemolysis.

In conclusion, this report agrees with previous findings that genetic modifiers can ameliorate the clinical severity of β-thalassaemia, even without obvious clinical symptoms in a prolonged steady state, which should be considered during prenatal diagnosis and genetic counselling of thalassaemia. However, the steady state can be disrupted during pregnancy. In addition, raising awareness of hyperhaemolysis among clinicians treating patients with thalassaemia is necessary.

ACKNOWLEDGEMENTS
This work was supported by the Medical Scientific Research Foundation of Guangdong Province (A2019076).

CONFLICT OF INTEREST
None.

AUTHOR CONTRIBUTIONS
Lou Jiwu analysed the clinical and genetic data and wrote the manuscript. Sun Manna and Lai Meixiang collected clinical data. Zhao Ying performed the Sanger sequencing. Liu Yanhui designed the study plan and critically reviewed the manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analysed in this study.

ORCID
Lou Jiwu https://orcid.org/0000-0001-8250-1498

REFERENCES
Chen, D., Zuo, Y., Zhang, X., Ye, Y., Bao, X., Huang, H., Tepakhan, W., Wang, L., Ju, J., Chen, G., Zheng, M., Liu, D., Huang, S., Zong, L., Li, C., Chen, Y., Zheng, C., Shi, L., Zhao, Q., … Xu, X. (2017). A genetic variant ameliorates β-thalassaemia severity by epigenetic-mediated elevation of human fetal hemoglobin expression. American Journal of Human Genetics, 101(1), 130–138. https://doi.org/10.1016/j.ajhg.2017.05.012
Danée, A., Inusa, B., Howard, J., & Robinson, S. (2015). Hyperhemolysis in patients with hemoglobinopathies: A single-center experience and review of the literature. Transfusion Medicine Reviews, 29(4), 220–230. https://doi.org/10.1016/j.tmrv.2015.06.001
Fanis, P., Kousiappa, I., Phylactides, M., Kyrii, A., Hadjigavriel, M., Christou, S., Sitarou, M., & Kleanthous, M. (2019). A novel
mutation in the erythroid transcription factor KLF1 is likely responsible for ameliorating β-thalassemia major. Human Mutation, 40(10), 1768–1780. https://doi.org/10.1002/humu.23817

Farrell, J. J., Sherva, R. M., Chen, Z. Y., Luo, H. Y., Chu, B. F., Ha, S. Y., Li, C. K., Lee, A. C., Li, R. C., Li, C. K., Yuen, H. L., So, J. C., Ma, E. S., Chan, L. C., Chan, V., Sebastiani, P., Farrer, L. A., Baldwin, C. T., Steinberg, M. H., & Chui, D. H. (2011). A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood, 117(18), 4935–4945. https://doi.org/10.1182/blood-2010-11-317081

Fraser, N. S., Knauth, C. M., Moussa, A., Dean, M. M., Hyland, C. A., Perkins, A. C., Flower, R. L., & Schoeman, E. M. (2019). Genetic variants within the erythroid transcription factor, KLF1, and reduction of the expression of lutheran and other blood group antigens: review of the In(Lu) phenotype. Transfusion Medicine Reviews, 33(2), 111–117. https://doi.org/10.1016/j.tmrv.2019.01.004

Galanello, R., Sanna, S., Perseu, L., Scottino, M. C., Satta, S., Lai, M. E., Barella, S., Uda, M., Usala, G., Abecasis, G. R., & Cao, A. (2009). Amelioration of Sardinian beta-thalassemia by genetic modifiers. Blood, 114(18), 3935–3937. https://doi.org/10.1182/blood-2009-04-217901

Lai, Y., Chen, Y., Chen, B., Zheng, H., Yi, S., Li, G., Wei, H., He, S., & Zheng, C. (2016). Genetic variants at BCL11A and HBS1L-MYB loci influence Hb F levels in Chinese Zhuang β-thalassaemia intermedia patients. Hemoglobin, 40(6), 405–410. https://doi.org/10.1080/03630269.2016.1253586

Liu, D., Zhang, X., Yu, L., Cai, R., Ma, X., Zheng, C., Zhou, Y., Liu, Q., Wei, X., Lin, L., Yan, T., Huang, J., Mohandas, N., An, X., & Xu, X. (2014). KLF1 mutations are relatively more common in a thalassaemia endemic region and ameliorate the severity of beta-thalassaemia. Blood, 124(5), 803–811. https://doi.org/10.1182/blood-2014-03-561779

Merrill, S. A., Brodsky, R. A., Lanzkron, S. M., & Naik, R. (2019). A case-control analysis of hyperhemolysis syndrome in adults and laboratory correlates of complement involvement. Transfusion, 59(10), 3129–3139. https://doi.org/10.1111/trf.15445

Razak, S., Murad, N., Masra, F., Chong, D., Abdullah, N., Jalil, N., Alauddin, H., Sabudin, R., Ithnin, A., Khai, L. C., Aziz, N. A., Muda, Z., Ibrahim, H., & Latiff, Z. A. (2018). Genetic modifiers of fetal haemoglobin (HbF) and phenotypic severity in beta-thalassemia patients. Current Molecular Medicine, 18(5), 295–305. https://doi.org/10.2174/1566524018666181004121604

Thornton, N. M., & Grimsmo, S. P. (2019). Clinical significance of antibodies to antigens in the ABO, MNS, PI PK, Rh, Lutheran, Kell, Lewis, Duffy, Kidd, Diego, Yt, and Xg blood group systems. Immunohematology, 35(3), 95–101.

Xiong, F., Sun, M., Zhang, X., Cai, R., Zhou, Y., Lou, J., Zeng, L., Sun, Q., Xiao, Q., Shang, X., Wei, X., Zhang, T., Chen, P., & Xu, X. (2010). Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China. Clinical Genetics, 78(2), 139–148. https://doi.org/10.1111/j.1399-0004.2010.01430.x

Xu, X. M., Zhou, Y. Q., Luo, G. X., Liao, C., Zhou, M., Chen, P. Y., Lu, J. P., Jia, S. Q., Xiao, G. F., Shen, X., Li, J., Chen, H. P., Xia, Y. Y., Wen, Y. X., Mo, Q. H., Li, W. D., Li, Y. Y., Zhuo, L. W., Wang, Z. Q., … Zhong, M. (2004). The prevalence and spectrum of α and β thalassaemia in Guangdong Province: implications for the future health burden and population screening. Journal of Clinical Pathology, 57(5), 517–522.

Yin, A., Li, B., Luo, M., Xu, L., Wu, L., Zhang, L., Ma, Y., Chen, T., Gao, S., Liang, J., Guo, H., Qin, D., Wang, J., Yuan, T., Wang, Y., Huang, W. W., He, W. F., Zhang, Y., Liu, C., … Zhong, X. (2014). The prevalence and molecular spectrum of alpha- and beta-globin gene mutations in 14,332 families of Guangdong Province, China. PLoS One, 9(2), e89855. https://doi.org/10.1371/journal.pone.0089855

How to cite this article: Jiwu L, Manna S, Lai M, Ying Z, Yanhui L. Hyperhaemolysis in a pregnant woman with a homozygous β0-thalassemia mutation and two genetic modifiers. Mol Genet Genomic Med. 2021;00:e1696. https://doi.org/10.1002/mgg3.1696